Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma

被引：8

作者：

Loft, Matthew ^{[1
,2
]}

Lee, Belinda ^{[1
,2
]}

Tie, Jeanne ^{[1
,2
,3
,4
]}

Gibbs, Peter ^{[1
,2
,3
]}

机构：

[1] Walter & Eliza Hall Inst Med Res, Syst Biol & Personalised Med Div, Parkville, Vic 3050, Australia

[2] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia

[3] Western Hlth, Dept Med Oncol, Footscray, Vic 3011, Australia

[4] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic 3000, Australia

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2019年 / 9卷 / 03期

关键词：

pancreatic cancer; circulating tumour DNA (ctDNA); biomarkers; liquid biopsy; personalised oncology; targeted therapy; intratumoural heterogeneity; molecular resistance; K-RAS MUTATIONS; CELL-FREE DNA; CANCER-PATIENTS; ADJUVANT CHEMOTHERAPY; LIQUID BIOPSY; PLASMA DNA; GEMCITABINE; METHYLATION; DIAGNOSIS; SERUM;

D O I：

10.3390/jpm9030037

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions.

引用

页数：9

共 61 条

[1] Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection [J].

Abbosh, Christopher ;

Birkbak, Nicolai J. ;

Swanton, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :577-586

[2] Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors [J].

Adalsteinsson, Viktor A. ;

Ha, Gavin ;

Freeman, Samuel S. ;

Choudhury, Atish D. ;

Stover, Daniel G. ;

Parsons, Heather A. ;

Gydush, Gregory ;

Reed, Sarah C. ;

Rotem, Denisse ;

Rhoades, Justin ;

Loginov, Denis ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Leshchiner, Ignaty ;

Kim, Jaegil ;

Stewart, Chip ;

Rosenberg, Mara ;

Francis, Joshua M. ;

Zhang, Cheng-Zhong ;

Cohen, Ofir ;

Oh, Coyin ;

Ding, Huiming ;

Polak, Paz ;

Lloyd, Max ;

Mahmud, Sairah ;

Helvie, Karla ;

Merrill, Margaret S. ;

Santiago, Rebecca A. ;

O'Connor, Edward P. ;

Jeong, Seong H. ;

Leeson, Rachel ;

Barry, Rachel M. ;

Kramkowski, Joseph F. ;

Zhang, Zhenwei ;

Polacek, Laura ;

Lohr, Jens G. ;

Schleicher, Molly ;

Lipscomb, Emily ;

Saltzman, Andrea ;

Oliver, Nelly M. ;

Marini, Lori ;

Waks, Adrienne G. ;

Harshman, Lauren C. ;

Tolaney, Sara M. ;

Van Allen, Eliezer M. ;

Winer, Eric P. ;

Lin, Nancy U. ;

Nakabayashi, Mari ;

Taplin, Mary-Ellen ;

Johannessen, Cory M. .

NATURE COMMUNICATIONS, 2017, 8

[3] Toward liquid biopsies in cancer treatment: application of circulating tumor DNA [J].

Ahlborn, Lise Barlebo ;

Ostrup, Olga .

APMIS, 2019, 127 (05) :329-336

[4] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].

ALMOGUERA, C ;

SHIBATA, D ;

FORRESTER, K ;

MARTIN, J ;

ARNHEIM, N ;

PERUCHO, M .

CELL, 1988, 53 (04) :549-554

[5]

[Anonymous], PANCREATIC ADENOCARC

[6] Proteomic and genomic profiling of pancreatic cancer [J].

Ansari, Daniel ;

Toren, William ;

Zhou, Qimin ;

Hu, Dingyuan ;

Andersson, Roland .

CELL BIOLOGY AND TOXICOLOGY, 2019, 35 (04) :333-343

[7] The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal [J].

Ballehaninna, Umashankar K. ;

Chamberlain, Ronald S. .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (02) :105-119

[8] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].

Bettegowda, Chetan ;

Sausen, Mark ;

Leary, Rebecca J. ;

Kinde, Isaac ;

Wang, Yuxuan ;

Agrawal, Nishant ;

Bartlett, Bjarne R. ;

Wang, Hao ;

Luber, Brandon ;

Alani, Rhoda M. ;

Antonarakis, Emmanuel S. ;

Azad, Nilofer S. ;

Bardelli, Alberto ;

Brem, Henry ;

Cameron, John L. ;

Lee, Clarence C. ;

Fecher, Leslie A. ;

Gallia, Gary L. ;

Gibbs, Peter ;

Le, Dung ;

Giuntoli, Robert L. ;

Goggins, Michael ;

Hogarty, Michael D. ;

Holdhoff, Matthias ;

Hong, Seung-Mo ;

Jiao, Yuchen ;

Juhl, Hartmut H. ;

Kim, Jenny J. ;

Siravegna, Giulia ;

Laheru, Daniel A. ;

Lauricella, Calogero ;

Lim, Michael ;

Lipson, Evan J. ;

Marie, Suely Kazue Nagahashi ;

Netto, George J. ;

Oliner, Kelly S. ;

Olivi, Alessandro ;

Olsson, Louise ;

Riggins, Gregory J. ;

Sartore-Bianchi, Andrea ;

Schmidt, Kerstin ;

Shih, Ie-Ming ;

Oba-Shinjo, Sueli Mieko ;

Siena, Salvatore ;

Theodorescu, Dan ;

Tie, Jeanne ;

Harkins, Timothy T. ;

Veronese, Silvio ;

Wang, Tian-Li ;

Weingart, Jon D. .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[9]

BURKI E, 1948, OPHTHALMOLOGICA, V115, P241

[10] K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer [J].

Chen, H. ;

Tu, H. ;

Meng, Z. Q. ;

Chen, Z. ;

Wang, P. ;

Liu, L. M. .

EJSO, 2010, 36 (07) :657-662

← 1 2 3 4 5 6 7 →